Assessment of the Therapeutic Effect of Polyethylene glycol and Lactulose in Patients with Hepatic Encephalopathy Assessment of the Therapeutic Effect of Polyethylene glycol and Lactulose
Novelty in Biomedicine,
Vol. 10 No. 1 (2022),
31 January 2022
,
Page 1-8
https://doi.org/10.22037/nbm.v10i1.34096
Abstract
Background: The mechanism of cerebral dysfunction in hepatic encephalopathy is unknown, although
ammonia produced by intestinal bacteria is an essential factor. This study was performed to compare the effect
of polyethylene glycol with lactulose in patients with hepatic encephalopathy.
Materials and Methods: In this interventional study, which was performed as a three-blind randomized
clinical trial, 60 patients with hepatic encephalopathy referred to Imam Hossein Hospital in Tehran were
randomly selected and divided into two groups receiving polyethylene glycol or lactulose were divided and the
levels of creatinine, ammonia, platelets, hemoglobin, albumin and bilirubin and Hepatic Encephalopathy
Scoring Algorithm, Model for End-Stage Liver Disease and Child-Turcotte-Pugh scores in the patients were
compared in the two groups.
Results: The results showed the frequency distribution of creatinine, ammonia, platelets, hemoglobin,
albumin, and bilirubin and Hepatic Encephalopathy Scoring Algorithm, Model for End-Stage Liver Disease,
and Child-Turcotte-Pugh scores of patients in the two groups were not statistically significant (P>0.05).
Conclusion: In general, based on the results of this study, it is inferred that polyethylene glycol and lactulose
have similar efficacy in patients with hepatic encephalopathy and, therefore, the use of each of them according
to the condition of patients and the discretion of the treating physician Recommended.
- Polyethylene glycol, Lactulose, Hepatic encephalopathy
How to Cite
References
Rahimi RS, Singal AG, Cuthbert JA, Rockey DC.et al. Lactulose vs Polyethylene glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727-33.
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is thr second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-55.
Melato M, Sasso F, Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. Zentralbl Pathol. 1993;139:25-30.
Graudal N, Leth P, Marbjerg L, Galleo AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230:165-71.
Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin liver dis. 2008;12:733-46.
Mathers C, Lopez A, Murray C. The burden of disease and mortality by condition Data, methods, and results for 2001. Oxford University press and the World Bank. 2006;45-93.
Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK. Et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106:1646-53.
Minino AM. Death in the United States, 2011.NCHS Data Brief. 2013;(115):1-8.
GBD 2013 Mortality and Causes of death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: asystemic analysis for the Global Burden of Disease study 2013. Lancet. 2015;385:117-71.
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-21.
Zenos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenteral. 2014;20:15532-8.
Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9.
Ferenci P, Lockwood A, Mullen k, Tarter R, Weissenborn k, Blei AT. Hepatic encephalopathy– definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World congresses of Gastroenterology, Vienna, 1998. Hepatology (Baltimore, Md). 2002;35:716-21.
Bajaj JS, WadeJB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (Baltimore, Md). 2009;50:2014-21.
Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005;42 Suppl 1: S45-53.
Romero-Gomez M, Boza F, Garcia- Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenteral. 2001;962718-23.
Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology (Baltimore, Md). 2007;45:549-59.
Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y.et al. Clinical efficasy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology (Baltimore, MD). 1997;26:1410-4.
Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31:537-47.
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenteral. 2014;20:5442-60.
Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenteral. 2012;18:767-77.
Kimer N, Krag A, Moller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Thear. 2014;40:123-32.
Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysis.
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2007.03464.x
Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis. 1996;16:329-38.
Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885-91.
Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenteral.2001;96:1968-76.
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy:systematic review of randomized trials. BMJ. 2004;328:1046.
Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G. et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy results of a randomized controlled trial. Gastroenteral Clin Biol. 1994;18:1063-8.
Hassanein T, Barakat F, Barret AC, Bortey E, Peterson C, Forbes WP. Su1687 Utility of the Hepatic Encephalopathy Scoring Algorithm (HESA) for Diagnosing Hepatic Enceohalopathy in a Randomized, Controlled Trial of Rifaximin vs Placebo. American Gastroenterological Association (AGA). 2013;144(5):997-8.
Naderian M, Akbari H, Saeedi M, Sohrabpour A. Polyethylene Glycol and Lactulose versus lactulose Alone in the Treatment of Hepatic Encephalopathy in Pationt with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East Journal of Digestive Diseases. 2017;9(1):12-19.
- Abstract Viewed: 102 times
- pdf Downloaded: 153 times